Peres Fernanda F, Lima Alvaro C, Hallak Jaime E C, Crippa José A, Silva Regina H, Abílio Vanessa C
Laboratory of Behavioral Neurosciences, Department of Pharmacology, Federal University of São Paulo, São Paulo, Brazil.
National Institute for Translational Medicine (INCT-TM, CNPq, FAPESP, CAPES), Ribeirão Preto, Brazil.
Front Pharmacol. 2018 May 11;9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018.
Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. Although the studies that investigate the effects of this compound on movement disorders are surprisingly few, cannabidiol emerges as a promising compound to treat and/or prevent them. Here, we review these clinical and pre-clinical studies and draw attention to the potential of cannabidiol in this field.
帕金森病和运动障碍等运动障碍是与氧化应激和神经退行性变相关的严重致残性疾病。在有可用药物时,这些疾病的药物治疗仍然主要是对症治疗,并非对所有患者都有益,且会引发严重的副作用。大麻二酚是一种来自大麻的非致幻化合物,具有抗精神病、抗焦虑、抗炎和神经保护作用。尽管研究该化合物对运动障碍影响的研究出奇地少,但大麻二酚已成为治疗和/或预防这些疾病的一种有前景的化合物。在此,我们综述这些临床和临床前研究,并提请关注大麻二酚在该领域的潜力。